Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10315703" target="_blank" >RIV/00216208:11130/15:10315703 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10315703

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MOU.0000000000000203" target="_blank" >http://dx.doi.org/10.1097/MOU.0000000000000203</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MOU.0000000000000203" target="_blank" >10.1097/MOU.0000000000000203</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?

Popis výsledku v původním jazyce

Purpose of reviewTrimodal therapy (TMT) is considered the most effective bladder-sparing approach for muscle-invasive urothelial carcinoma of the bladder (MIBC) and an alternative to radical cystectomy. The purpose of this article was to review and summarize the current knowledge on the equivalence of TMT and radical cystectomy based on the recent literature.Recent findingsTMT consists of a maximal transuretral resection of the bladder, followed by a concurrent radiotherapy and chemotherapy, limiting salvage radical cystectomy to nonresponder tumors or muscle-invasive recurrence. In large population studies, less than 6% of the patients with nonmetastatic MIBC receive a chemoradiation therapy and this rate is stable. A growing body of evidence exists that TMT provides good oncologic outcomes with low morbidity when compared with radical cystectomy. TMT requires, however, a close follow-up because of the high risk of local recurrence and salvage radical cystectomy in up to 30% of the pa

Název v anglickém jazyce

Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?

Popis výsledku anglicky

Purpose of reviewTrimodal therapy (TMT) is considered the most effective bladder-sparing approach for muscle-invasive urothelial carcinoma of the bladder (MIBC) and an alternative to radical cystectomy. The purpose of this article was to review and summarize the current knowledge on the equivalence of TMT and radical cystectomy based on the recent literature.Recent findingsTMT consists of a maximal transuretral resection of the bladder, followed by a concurrent radiotherapy and chemotherapy, limiting salvage radical cystectomy to nonresponder tumors or muscle-invasive recurrence. In large population studies, less than 6% of the patients with nonmetastatic MIBC receive a chemoradiation therapy and this rate is stable. A growing body of evidence exists that TMT provides good oncologic outcomes with low morbidity when compared with radical cystectomy. TMT requires, however, a close follow-up because of the high risk of local recurrence and salvage radical cystectomy in up to 30% of the pa

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Opinion in Urology

ISSN

0963-0643

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

476-482

Kód UT WoS článku

000364132200017

EID výsledku v databázi Scopus

2-s2.0-84942592096